Wandercraft acquires Ekso Bionics to build global exoskeleton leader
What's the deal? French robotics firm Wandercraft has acquired US-based Ekso BionicsDealroom has a profile for this one. Try Dealroom → from a subsidiary of ChronoScale Holdings CorporationDealroom has a profile for this one. Try Dealroom →, uniting two makers of medical exoskeletons. The deal, announced October 1, 2026, was undisclosed. Both companies build wearable robotic systems that help people with mobility impairments stand and walk.
What's the endgame? Wandercraft wants to cover what it calls the "continuum of care," from clinical rehabilitation to everyday personal mobility. The combination pairs Wandercraft's robotics and physical AI expertise, plus its strength in EMEA, with Ekso Bionics' US presence and clinical reach.
What changes? The combined company will support four products: rehabilitation platforms Atalante X and EksoNR, and personal devices Eve and Indego Personal. These hold US Food and Drug Administration clearances and CE marking covering stroke, spinal cord injury, multiple sclerosis, and acquired brain injury.
Atalante X and EksoNR already serve patients at more than 700 rehabilitation centres worldwide. Wandercraft said it intends to keep supporting all four products and the clinicians and patients who rely on them.
Why now? Reimbursement is opening up. In the US, Medicare covers qualifying personal exoskeletons under its brace benefit category for eligible patients. Greater scale lets the combined company push for broader coverage globally.
"We share a vision for how robotics can empower people whose mobility has been unfairly limited by injury or disease," said Matthieu Masselin, chief executive officer and co-founder of Wandercraft. He added the deal creates "an exceptional opportunity to expand access to robotic mobility worldwide."
Scott Davis, of the go-forward Ekso Bionics, said joining Wandercraft "represents an exciting next chapter." He noted Ekso has spent two decades building clinical evidence "that has earned the trust of clinicians and the people who rely on our products."
The signal: Medical exoskeletons are consolidating as the technology matures and payers begin to cover it. By merging a European robotics leader with a US clinical incumbent, the deal aims to turn a fragmented field into a single global player spanning hospital rehabilitation and the home.
Read more: finance.yahoo.com
Image credit: Ekso Bionics
